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Abstract: Background: The development of nanostructures (nanoparticles and nanocap-
sules) is one of the most important pipelines of research of pharmaceutical technology.  
Methods: These nanotechnology pharmaceuticals allow the vectorization of drugs to tis-
sues or cells target, allowing thus actions more specific and therapeutically active di-
rected by molecules.  
Results: The use of molecules with an affinity for membrane receptors expressed in spe-
cific excess in tumor cells, monoclonal antibodies, or proteins, among others, is common 
for this purpose. In addition, these nanosystems allow to deliver drugs that could be the 
basis of the pharmacological treatment of many disorders of genetic origin in the future: 
biomolecules.  
Conclusion: The future scope of drug vectoring systems to target drug delivery using 
nanotechnologies can increase the control of pharmacokinetic parameters of chemothera-
peutic agents. 
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1. INTRODUCTION 
Chemotherapeutic anti-cancer drugs have mul-
tiple drawbacks, including severe adverse effects 
and suboptimal pharmacotherapeutic efficacy. 
Pharmaceutical nanotechnology might assist to 
improve pharmacokinetic processes such us bio-
distribution and accumulation of chemotherapeutic 
drugs, and thus are able to improve the balance 
between efficacy and toxicity. Several types of 
pharmaceutical nanotechnology drugs have been 
assessed, including liposomes, polymer-drug con-
jugates and polymeric micelles, which are based 
on strategies such as passive targeting, active tar-
geting and triggered release for improved admini-
stration of the target drug to the tumor [1-4]. Tu-
mors and metastases are highly heterogeneous, so  
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it is important to integrate imaging properties into 
pharmaceutical nanotechnology formulations in 
order to allow noninvasive and quantitative evalu- 
ation of targeting efficiency. By allowing pre-
selection of patients, these next-generation nano- 
theranostics are useful for facilitating clinical 
translation and customizing pharmaceutical nano- 
technology treatments [5]. 
On the other hand, hematologic malignancies 
are a group of diseases characterized by the clon-
ally proliferation of blood-forming cells. Malig-
nant blood cells are classified as myeloid or lym-
phoid cells, depending on the origin of their stem 
cells. Lymphoid malignancies are characterized by 
the accumulation of lymphocytes in the blood-
stream, bone marrow or lymph nodes and organs. 
Several of these diseases are associated with 
chromosomal translocations, which cause gene 
fusion and amplification of expression, while oth-
ers are characterized by aberrant expression of on-
cogenes. In general, these genes play an important 
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role in the development and maintenance of ma-
lignant clones. The discovery of antisense oli-
gonucleotides and RNA interference mechanisms 
offer new tools for specifically manipulating gene 
expression. Systemic administration of inhibitory 
oligonucleotides molecules for the manipulation of 
gene expression in lymphocytes has great potential 
to facilitate the development of an oligonucleo-
tide-based therapy platform for lymphoid blood 
cancer. However, lymphocytes are among the 
most difficult targets for oligonucleotide delivery, 
as they are resistant to conventional transfection 
reagents and are dispersed throughout the body, 
making it difficult to locate or successfully distrib-
ute oligonucleotide payloads via systemic admini-
stration [6]. 
Current pharmaceutical research is mainly fo-
cused on the vectorization of drugs. Actually, dis-
eases that cause the greatest number of deaths in 
our country are, in their genetic origin, such as the 
many types of cancer that are the result of muta-
tions in the DNA. As a result, medical devices able 
to vectorize the drug into the organs, tissues or cells 
is a must in medical condition that is not covered; if 
so, would improve the current pharmacological 
treatments and increase the survival of many dis-
eases non-curable today. The bulk of this research 
focuses on the use of nanotechnology, with the 
formulation of nanoparticles or nanocapsules, as a 
basis for pharmaceutical drugs to drive the drugs. 
Many health-care professionals might confuse 
concepts of nanoparticles (or nanoes beasts) and 
nanocapsules, but both are different. In both nano-
systems, ranging in size from 10 to 1000 nm, the 
drug can be found attached to the surface of the 
nanoparticle, to be encapsulated in its or forming 
part of the matrix. Thus, the difference is not in 
where the drug is, but in the composition of the 
nanosystem itself. On the one hand, nanoparticles 
are small solid matrix particles in which the drug 
may be trapped in the polymer network, dissolved 
therein or adsorbed on its surface. They may be 
lipid nanospheres, a polyelectrolyte complex or a 
nanogel. On the other hand, nanocapsules are based 
on a liquid or semi-solid core (wrapped) by a solid 
polymer membrane. The core may be oil (to encap-
sulate lipophilic drugs) or aqueous (to encapsulate 
hydrophilic drugs) [7]. In both cases, depending on 
the components of the polymer membrane or the 
matrix, the particle will tend to target one or another 
tissue, release the drug within a given time, etc. So-
called “passive targeting” is based on drug accumu-
lation in the areas around the tumors with leaky  
vasculature. The rate of drug release is dependent  
on how it diffuses out of the polymer. “Active  
targeting” is used to describe specific interactions  
between drug/drug carrier and the target cells, usu-
ally through specific ligand-receptor interactions. 
To explain the advantages of these nanosystems, 
it is well known that chemotherapeutic agents used 
to have little specificity for tumor, and therefore, 
had high toxicity. These two facts add that chemo-
therapy to treat cancerous processes is very hard to 
bear on the part of the patient, with a large number 
of adverse effects that directly influence their 
Health-Related Quality of Life (HRQOL). Thus, 
finding a system that vehicles the antitumor drug 
and releases it specifically in the tumor cells has 
become one of the most important objectives of 
biomedical research. Another major problem with 
anti-cancer chemotherapy begins when cells be-
come drug-resistant, which typically upregulate P-
glycoprotein. However, the lack of overexpression 
of surface biomarkers has limited targeted therapy 
of drug-resistant cancers [8]. 
1.1. Drug Vectoring Systems Vectorization Based 
on Folate Receptors 
Folic acid is a water-soluble vitamin (vitamin 
B9) necessary for DNA replication. Its deficiency 
impairs cell synthesis and division, particularly 
affecting rapidly dividing cells, such as bone mar-
row cells. Furthermore, it plays a particularly im-
portant role during fetal and embryonic develop-
ment, since its deficiency can lead to malforma-
tions. 
To transport folic acid inward, the cell needs a 
membrane-specific receptor, which in many tumor 
cells is overexpressed (from 100 to 300 times), as 
in many kidney, brain, breast, or lung cancers [9]. 
This overexpression can be exploited by pharma-
ceutical companies to manufacture nanoparticles 
that specifically recognize tumor cells, and thus 
vectorize the drug to this specific cell type. Thus, 
this vectorization is achieved by introducing fo-
late-type ligands into the membranes of the 
nanoparticles [10, 11]. 
1.2. Vectorization Based On Monoclonal Anti-
bodies 
A second widely used and researched strategy 
is based on monoclonal antibodies (mab). These 
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proteins are of the IgG type, and contain, like all 
antibodies, two regions: a fragment that recognizes 
specific to an antigen (Fab) and a constant, com-
plement-fixing (Fe) fragment. Each type of tumor 
is the result of a mutation or mutation of the ge-
netic material of the cells, and this leads, in many 
cases, to the overexpression or anomalous expres-
sion of some proteins that can act as antigens. This 
is the case, for example, of HER2 in breast, or the 
epidermal growth factor receptor in lymphoma. 
Producing specific antibodies against these anti-
gens and incorporating them into the surface of 
nanosystems may represent a leading strategy for 
drug vectorization, since it can act very specifi-
cally in cells that overexpress the antigen. Even so, 
the problem of this kind of vectorization is the 
practical difficulties and the economic costs re-
lated, due to scale up and production of these 
nanosystems in an industrial way is almost impos-
sible at present. 
For this reason, much of the current biomedical 
research is oriented to the search of specific mem-
brane antigens expressed in certain types as well 
as in the development of humanized chemistry de-
rivatives to reduce immunogenicity and the devel-
opment of new formulations and systems incorpo-
rating the antibodies with consistent, reproducible 
and scalable techniques at the industrial level [12, 
13]. 
1.3. Aptamer-Based Vectorization 
Aptamers (also called chemical antibodies) are 
macromolecules containing a single strand of 
DNA or RNA, capable of recognizing, in a spe-
cific, stable and high affinity manner, several types 
of target molecules, such as membrane proteins. 
Among their advantages, these systems exhibit 
easy chemical isolation, selective binding affinity, 
small size and absence of immunogenicity. In ad-
dition, the aptamers can be modified superficially 
by functional groups to favor conjugation with 
nanosystems. Therefore, they are a promising vec-
toring system for drug vectorization and diagnosis 
in cancer therapy [14, 15]. 
1.4. Dendrimer-Based Vectoring 
The dendrimers are monodisperse three-dimen- 
sional macromolecules of arborescent construc-
tion, with suitable properties for drug encapsula-
tion at nanometer scale. Its nucleus is hydrophobic 
and its surface is hydrophilic. The drug may be in 
the nanoparticle, depending on the nature of the 
drug, the components of the nanosystem and the 
method of manufacture. In these cases, the use of 
polyamidoamine polymers (PAMAM) is very fre-
quent to conjugate chemotherapeutic agents. Fluo-
rescein isocyanate (PAMAM-FITC) conjugated to 
ligands, such as phytic acid or biotin, is also used 
to carry drugs such as taxol to tumor cells [16]. In 
addition, dendrimers are used for other purposes, 
such as controlled release of ocular polycarpin 
[17] or as a carrier in gene therapy. 
1.5. Integrin-Based Vectoring 
Integrins are a family of cell adhesion receptors 
that bind to the extracellular matrix and ligands of 
the cell surface. They are proteins that play a role 
in the development of cancer, specifically in angi-
ogenesis and metastasis. For example, integrin 
αvβ3 is known to play a key role in the formation 
of new vessels in tissues with tumor cells. As re-
ceptors for a variety of extracellular matrix pro-
teins that have the arginine-glycine-aspartic (Arg-
Gly-Asp) sequence, these integrins mediate the 
migration of cells to other tissues, their growth and 
their survival. 
This natural process in cancer can be used to 
transport drugs through nanosystems to tumor 
cells, since the expression of a synthetic peptide 
with the sequence Arg-Gly-Asp can direct the 
nanosystem to the tumor cell, thus inhibiting tu-
mor growth and its proliferation [18]. 
1.6. Receptor-Based Vectorization of the 
Vasoactive Intestinal Peptide (VIP) 
VIP is a neuropeptide of 28 amino acids gluca-
gon-secretin widely distributed by the central and 
peripheral nervous system. It has been described 
that VIP receptors are expressed 5-fold in breast 
cancer tumor cells. This fact can be used to carry 
nanoparticles to said tumor cells. In some investi-
gations, through PEG + VIP + radionuclide struc-
tures, active and passive inhibition of breast cancer 
in rats could be produced. Nevertheless, the vec-
torization based on VIP has an important limita-
tion: the difficulty to cross the blood-brain barrier, 
and the rapid elimination and degradation of this 
system [19, 20]. 
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2. BIOMOLECULES AS THERAPEUTIC 
AGENTS 
Reviewing current research, one can observe as 
a new paradigm in the field of pharmacy caused by 
the boom of the different advances in the field of 
molecular biology. The discovery of genomic si-
lencing with small interference RNA (siRNA) or 
the current discovery of the CRISPR-Cas9 system 
as a tool for gene modification of cells has recently 
been discovered as potential therapeutic mole-
cules. For example, if you have a specific gene 
whose expression causes a large part of the devel-
opment of a cancer, with its silencing would be 
possible to reverse it. So it is no foolish thing to 
think that in a few years diseases of origin genetics 
are treated with biomolecules and not with drugs 
of chemical origin. 
To convey these biomolecules, classical dosage 
forms (tablets, capsules, solutions, suspensions or 
emulsions) are ineffective in administering bio-
molecules without anything stabilizing them. In 
such dosage forms these molecules are degraded 
rapidly. In this field, the nanosystems explained 
play an important role. The use, for example, of 
cSLN (cationic solid lipid nanoparticles) is widely 
used in research as a transport system for such 
biomolecules [21, 22]. These nanoparticles, with 
the correct formulation, can transfect the cells and 
release the previously loaded biomolecules, in or-
der to achieve, for example, the silencing of a 
gene. These cSLNs may become the most used 
pharmaceutical base for gene therapy, since their 
low immunogenicity makes them vectors with 
more future prospects than viral vectors. While it 
is true that viral vectors have a much higher trans-
fection efficiency, it is only a matter of time before 
studies conducted by multiple research groups 
succeed in developing nanoparticle formulations 
with a sufficiently high transfection efficiency to 
be one Reality. If further said biomolecules are 
combined with formulations capable of recogniz-
ing a particular type of cells (e.g., tumor cells), it 
appears that the development of effective cancer 
therapies may be a reality within a few years. 
3.  NANOSYSTEMS IN THE MARKET 
While it is true that a great deal of research is 
being done, the success rate is relatively low. For 
example, 10,566 articles related to nanoparticles 
and cancer were found in a Medline/PubMed 
search, and 19,234 articles were found in Embase; 
the search strategy string was ("Nanoparti-
cles"[Mesh]) AND "Neoplasms"[Mesh]) for Pub-
Med, and ('nanoparticle'/exp AND 'neoplasm'/exp) 
through Elsevier’s comprehensive biomedical lit-
erature database. In December 2016, 1,843 clinical 
trials were registered at clinicaltrials.gov, three 
with nanoparticles. Therefore, clinical trials per-
formed account for about 2% of published articles. 
Formulations based on nanosystems can also be 
found in the market. For example, The European 
Commission granted a marketing authorisation 
valid throughout the European Union for Abrax-
ane, a formulation of paclitaxel stabilized in albu-
min nanoparticles, or Caelyx, an injection of pegy-
lated liposomes of doxorubicin. Paclitaxel-albumin 
which, by not including cremophor in its formula-
tion, and allows to obviate the premedication of 
conventional paclitaxel. In a phase III comparative 
study against paclitaxel, paclitaxel-albumin ob-
tained a higher rate of responses and a longer time 
to progression. On the other hand, it was also 
compared with docetaxel in a phase II study, 
achieving a better result in disease-free survival. 
However, these two formulations do not use nano-
systems to vector drugs into tumor cells, but are 
used to improve the physicochemical (as in 
Abraxane) or pharmacokinetic (as Caelyx) charac-
teristics of the drugs [23-25]. 
Combination anticancer pharmacotherapy is 
promising for generating synergistic anticancer 
effects, maximizing the effect of treatment, and 
overcoming multidrug resistance. Nanostructure 
lipid carriers, solid and liquid lipid compounds, 
and surfactants are carriers of potentially good col-
loidal drugs [26]. 
It is clear that many resources need to be in-
vested in biomedical research in order to achieve 
the vectorization of drugs. Hundreds of scientific 
articles are constantly published in this regard, 
showing that many research groups are investing 
efforts to achieve this [27-30]. Furthermore, some 
formulations are already in preclinical and clinical 
phases, although none have yet been achieved to 
be commercialized. Little by little progress is 
made in the knowledge of these processes, and 
pharmaceutical and biomedical research strives for 
this knowledge is reflected in a better quality of 
life and survival of our targets: the patients. 
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CONCLUSION & FUTURE DEVELOPMENTS 
The important developments made on the topic 
discussed in this article, surely help researchers, 
academicians and other experts in cancer therapy, 
especially for pharmaceutical oncology treatment. 
The future scope of drug vectoring systems to 
target drug delivery using nanotechnologies can 
increase the control of pharmacokinetic parameters 
of chemotherapeutic agents. Chemotherapy devel-
opments in current and future nanomedicine, 
namely strategies to target drug delivery, are be-
coming important tools for medicine and phar-
macy, mainly in oncology treatment framework, 
leading to fundamental breakthroughs in terms of 
more effective therapeutics in cancer. However, 
the impact on budget might change the focus to the 
most efficiency. 
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